Here’s why the Mesoblast (ASX:MSB) share price is sinking today

This comes after the release of it’s respiratory function results earlier.

| More on:
Scientists working on a screen in laboratory

Image source: Getty Images

The Mesoblast Limited (ASX: MSB) share price has sunk more than 4% in today’s trading session.

Shares in the biotechnology company are struggling today after Mesoblast released an announcement earlier today.

Let’s take a look at what Mesoblast announced and why investors are jumping off.

What’s driving the Mesoblast share price lower

Earlier today, Mesoblast released respiratory function results from its COVID-19 trial.

The clinical results relate to Mesoblast’s randomized controlled trial of its remestemcel-L product on ventilator dependent COVID-19 patients. These patients have also been diagnosed with acute respiratory distress syndrome (ARDS).

Mesoblast reported that remestemcel-L improved respiratory function in patients under 65 years old. In patients older than 65 years old, Mesoblast noted that remestemcel-L improved respiratory function at day 7.

Other secondary outcome results indicated that patients under 65 who received dexamethasone in addition to remestemcel-L reported improved respiratory function.

Mesoblast noted that the company has entered into a license and collaboration agreement with pharmaceutical giant Novartis. The agreement involved the development, manufacture, and commercialisation of remestemcel-L.

The company noted that the commercialisation of remestemcel-L will initially focus on the treatment of ARDS.

However, Mesoblast noted that the agreement remains subject to certain conditions, including analysis of results from the COVID-19 ARDS trial.

Although the announcement was marked ‘non-sensitive’, investors don’t seem too impressed by the results. Clinical outcomes were also presented by Mesoblast Chief Executive Officer, Dr Silviu Itescu at the Pulmonary Disease Conference.

Snapshot of the Mesoblast share price

Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases.

The company was a favourite among retail investors last year after it announced promising results for its remestemcel-L treatment for COVID-19.

After the initial euphoria which saw the Mesoblast share price hit a six-year peak in September last year, shares in the biotech have struggled. Shares in Mesoblast are trading more than 60% lower from their September highs.

As a result, Mesoblast has been one of the worst performers among healthcare companies on the S&P/ASX 200 Index (ASX: XJO) in FY21.

The Mesoblast share price has been plagued by various registration issues and has faced multiple class actions in the US.

At the time of writing, the Mesoblast share price is trading around 4% lower for the day, near its intra-day low of $1.89.

Should you invest $1,000 in Mesoblast right now?

Before you consider Mesoblast, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News